Familial invasive and borderline ovarian tumors by proband status, age and histology
Version of Record online: 1 APR 2003
Copyright © 2003 Wiley-Liss, Inc.
International Journal of Cancer
Volume 105, Issue 5, pages 701–705, 10 July 2003
How to Cite
Hemminki, K. and Granström, C. (2003), Familial invasive and borderline ovarian tumors by proband status, age and histology. Int. J. Cancer, 105: 701–705. doi: 10.1002/ijc.11151
- Issue online: 30 APR 2003
- Version of Record online: 1 APR 2003
- Manuscript Accepted: 7 FEB 2003
- Manuscript Revised: 30 JAN 2003
- Manuscript Received: 4 NOV 2002
- BRCA1/2 mutations;
- ovarian cancer;
- family history;
Age-specific familial risks in ovarian cancer have not been assessed by histologic types of medically verified cancers. We used the nationwide Swedish Family-Cancer Database on 10.2 million individuals and 19,175 invasive and 3,436 borderline ovarian cancers to calculate, by affected family members, standardized incidence ratios (SIRs) and 95% confidence intervals (CIs) for familial ovarian cancer in 0–66 year old daughters. SIRs for all invasive ovarian cancer were 2.68 (95% CI 2.22–3.21) by ovarian cancer in mother, 2.94 (1.40–5.94) by an affected sister and 24.03 (6.12–74.46) by both an affected mother and sister. The population-attributable fraction from mothers was 2.52%. Seropapillary cystadenocarcinoma showed the highest familial risk, but the effect of histopathol subtype could not be fully assessed because of lack of data in probands. Age-specific data showed some early-onset components and an unusual maximal incidence in the 40s. A comparison to an earlier study on BRCA1/2 mutation analysis and relative risks of ovarian and breast cancer suggests that these mutations could account for 26% of the familial aggregation of ovarian cancer. Histopathology and age of onset appear to be important attributes of familial ovarian cancer, suggesting that further gene identification efforts should target a specific histopathology in early-onset patients. © 2003 Wiley-Liss, Inc.